Gemphire Therapeutics (GEMP): Raising PT To $17 On Stronger Data - Jefferies

October 17, 2016 8:36 AM EDT Send to a Friend
Jefferies analyst, Matthew Andrews, reiterated his Buy rating on shares of Gemphire Therapeutics (NASDAQ: GEMP) and raised his price target ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login